Amlx forecast


Aime
Amylyx Pharmaceuticals Inc. (AMLX) is forecasted to have a net loss of $118.79 million, a total revenue of $88.64 million, and a diluted EPS of -$1.75 as of Q1 2024.
stock code | stock name | Total Revenue[20240331] | Net Income[20240331] | Diluted EPS[20240331] |
---|---|---|---|---|
AMLX.O | Amylyx Pharmaceuticals | $88.64 million | $-118.79 million | $-1.75 |
- Financial Performance: The company has reported a net loss of $118.79 million, which is a significant amount compared to the previous quarter's net loss of $6.60 million. This indicates that the company's financial performance is deteriorating. The diluted EPS is -$1.75, reflecting a deep loss per share.
- Revenue Trends: The total revenue for the quarter was $88.64 million, which is a decrease from the previous quarter's revenue of $102.7 million. This suggests that the company's revenue is not growing significantly.
- Growth Rates: The net income year-on-year growth rate is -1.09%, and the total revenue year-on-year growth rate is -16.82%. These negative growth rates indicate that the company is experiencing a decline in financial performance.
- Analyst Sentiments: The average analyst price target is $6.2, with a high forecast of $8.00 and a low forecast of $3.00. This suggests that analysts have a wide range of expectations for the stock's future performance.
- Stock Performance: The 5-day moving average is $2.68, and the 10-day moving average is $2.92. The stock has experienced a significant decline, with a 36.65% interval percentage change.
In conclusion, Amylyx Pharmaceuticals is forecasted to continue its current financial trajectory, with a net loss and negative growth rates in revenue and diluted EPS. Analysts have a wide range of expectations for the stock's future performance, with some predicting a potential upside. Investors should consider the company's financial performance and the specific risks and opportunities within the pharmaceutical industry when evaluating the stock's potential.
Continue this conversation 

Explore
Screener
Analysis
Learn
News